替罗非班联合低分子肝素治疗急性冠状动脉综合征临床疗效观察  

Efficacy of tirofiban combined with low-molecular-weight heparin in treatment of acute coronary syndrome

作　　者：龚鸿霞[1] 曹晓亮[1] 陈雯艾[1] 

机构地区：[1]义乌市中心医院综合病区,322000

出　　处：《中华老年医学杂志》2014年第2期147-149,共3页Chinese Journal of Geriatrics

基　　金：浙江省医药卫生科技计划项目（2010SSA009）;2012年义乌市第二批科研计划项目（12-322）

摘　　要：目的观察替罗非班联合低分子肝素治疗急性冠状动脉（冠脉）综合征的临床治疗效果及其安全性。方法选取本科室2011年1月至2013年1月间收治的老年急性冠脉综合征患者138例为研究对象，随机分为观察组和对照组。其中观察组80例，在常规治疗的基础上，给予替罗非班和低分子肝素治疗；对照组58例，在常规治疗的基础上，给予低分子肝素治疗；对比分析两组患者临床治疗效果及其不良反应发生情况。结果观察组临床治疗总有效率显著比对照组临床治疗总有效率高，差异有统计学意义（X2=8．589，P=0．003）；观察组24h心绞痛发作次数、心电图ST段下降值和肌钙蛋白T峰值改善明显优于对照组相应指标，差异有统计学意义（P〈0．05）。观察组血小板计数与对照组比较，差异无统计学意义（t=0．294，P=0．385）。观察组不良反应发生率与对照组比较，差异无统计学意义（X2=0．747，P=0．387）。结论替罗非班联合低分子肝素治疗急性冠脉综合征，可提高临床治疗效果，改善患者相关临床症状和体征，安全性好，值得临床应用。Objective To observe the efficacy and safety of tirofiban combined with low- molecular-weight heparin in treatment of acute coronary syndrome. Methods 138 patients with acute coronary syndrome were divided into two groups（observation group and control group）. In observation group, 80 cases were treated with tirofiban combined with low-molecular-weight heparin on the basis of conventional therapy. In control group, 58 cases were treated with low-molecular- weight heparin on the basis of conventional therapy. The efficacy and safety were compared between the two groups. Results The total efficacy was higher in observation group than in control group （X2= 8. 589, P〈0.01）. The improvement of 24 h anginal attacks, decrease in values of ECG ST segment and cardiac troponin T value were better in observation group than in control group（all P〈 0.05）. The blood platelet count and adverse reactions were not different between the two groups（t= 0. 294,）X2 = 0. 747, both P 〉 0.05 ）. Conclusions Tirofiban combined with low-molecular-weight heparin is effective and safe in the treatment of acute coronary syndrome. It can increase the clinical effect, improve clinical symptoms and signs in the patients, and is worthy of clinical application.

关 键 词：急性冠状动脉综合征 肝素 低分子量 血小板聚集抑制剂 

分 类 号：R541.4[医药卫生—心血管疾病]